Loading ....
Contact us to order
Tel
+1 866.986.9598
Yeasen
view supplier detailsCredit card payments now incur a 3% fee.
Yeasen
view supplier detailsCredit card payments now incur a 3% fee.
| Mfr.No. | 10603ES10, 10603ES05, 10603ES60, 10603ES20 |
| Description |
RNase Inhibitor is a specific ribonuclease (RNase) inhibitor found in human placenta. The principle of its specific inactivation of RNase is to bind non-covalently with RNase to form a complex, causing RNase to become inactive. This product is a recombinant mouse RNase inhibitor expressed and purified in a soluble form in E. coli, capable of broadly inhibiting various types of RNases (RNase A, B, C). Tested with RT-PCR and RT-qPCR, this product is compatible with Hifair® III Reverse Transcriptase (Cat#11111ES) and various DNA Polymerases. Compared to human RNase inhibitors, this product lacks two cysteine residues that are highly sensitive to oxidation in human proteins, thus possessing greater antioxidant activity. Additionally, it is more suitable for experiments with high sensitivity to DTT, such as qPCR. This product can be used in experiments such as first-strand cDNA synthesis, separation of polyribosomes, in vitro transcription, and in vitro cell-free translation systems. Features1.Broad-spectrum RNase inhibitory activity: Capable of inhibiting RNases including RNase A, RNase B, RNase C, and others.2.Compatible with a wide range of reaction conditions: Active under pH conditions from 5.0 to 9.0 and temperatures from 25°C to 60°C, suitable for thermophilic reverse transcriptases (55°C-60°C). 3.Compatible with a broad spectrum of downstream experiments: No impact on the enzymatic activity of SP6, T7, or T3 RNA polymerases, AMV, M-MLV reverse transcriptases, and Taq DNA polymerases. 4.Scalable production: Single-batch production capacity reaches 2 billion units, ensuring product uniformity, stability, and timely supply. 5.Batch-to-batch stability: Mature protein expression and purification platform, compliant with the ISO 13485 quality management system, quality control testing is conducted according to quality standards to ensure the stability of products between batches. 01 No exonuclease, incision enzyme residue  Figure: Detection of MRI nuclease (in a 20 μl reaction system, 200 U of MRI and 0.5 μg of λDNA-HindⅢ digest were added, incubated at 37°C for 4 hours) and nicking enzyme residual activity (in a 20 μl reaction system, 200 U of this enzyme and 0.5 μg of plasmid DNA were added, incubated at 37°C for 4 hours) shows no residual activity. Note: N represents the negative control; 1, 2, 3 represent three different batches. 02 No RNase enzyme residue  Figure: 20 μl reaction system added 200 U MRI and 0.5 μg 293T RNA, incubated at 37℃ for 4 hours, agarose gel electrophoresis RNA band did not change, there was no RNase residue. Note: N stands for negative control; 1, 2, and 3 are batches. 03 RNase enzyme inhibition ability comparable to competing brands  Figure: Using the influenza A virus culture supeatant as a template, the RT-qPCR reaction was performed using the Hifair® V Multiplex One Step RT-qPCR Probe Kit (UDG Plus) (Cat#13650ES) to validate the RNaseA digestion capability of MRI. The results indicated that Yeasen MRI's inhibitory capacity against RNaseA is comparable to that of similar inteational competitive products. Note: Yeasen Control represents 8 U MRI + 0 ng RNaseA; Yeasen represents 8 U MRI + 60 ng RNaseA; R* Control represents 8 U of a similar competitive product + 0 ng RNaseA; R* represents 8 U of a similar competitive product + 60 ng RNaseA. |
| Combination SKU | Supplier No. | Size | Your price | Quantity | |
|---|---|---|---|---|---|
| BHZ20800018-1 | 10603ES10 | 10KU | $145 |
|
Add to Cart |
| BHZ20800018-2 | 10603ES05 | 2KU | $35 |
|
Add to Cart |
| BHZ20800018-3 | 10603ES60 | 100KU | $1065 |
|
Add to Cart |
| BHZ20800018-4 | 10603ES20 | 20KU | $285 |
|
Add to Cart |
